Join us in-person in Berlin, Germany for the ESMO Congress 2025.
Evotec at ESMO Congress 2025
e-Poster Presentation
Exploratory Biomarkers Evaluation to Enhance Characterization and Explore Treatment Response Prediction in Metastatic Ovarian Cancer Patients Undergoing Therapy With EVT801, a Highly Selective VEGFR-3 Inhibitor
Location: Hall 25
Co-authored by Evotec and Kazia Therapeutics
Presentation
Evotec offers industry-leading capabilities in Oncology and Immuno-Oncology, combining advanced in vivo models, deep immunology expertise, and translational platforms
- Broad model portfolio: xenografts, syngeneic, humanized mice, cancer vaccines
- IO innovation: immune cell engagers, checkpoint inhibition, T-cell targeting
- Translational edge: biomarker strategies, patient-derived assays, imaging, and PK/PD
Explore how we accelerate discovery from target to clinic, backed by a strong track record and global partnerships.
